ECX — Epigenomics AG Income Statement
0.000.00%
Last trade - 00:00
- €1.41m
- -€1.82m
- €0.49m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.53 | 1.13 | 0.842 | 6.2 | 0.485 |
Cost of Revenue | |||||
Gross Profit | 1.09 | 0.872 | 0.697 | 6.07 | 0.365 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 14.4 | 15.8 | 12.5 | 8.56 | 12.5 |
Operating Profit | -12.9 | -14.7 | -11.6 | -2.35 | -12.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.4 | -14.6 | -11.7 | -2.41 | -12.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.7 | -17 | -11.7 | -2.43 | -12 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.7 | -17 | -11.7 | -2.43 | -12 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.7 | -17 | -11.7 | -2.43 | -12 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -74.1 | -72 | -39.8 | -4.32 | -14.8 |
Dividends per Share |